# US 2004/0024003 A1 · Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0024003 A1
- Document ID: US20040024003A1
- Status: Published application
- Kind: A1
- Application number: 10/149,980
- Filed: 2003-07-11
- Published: 2004-02-05
- Earliest claimed: 1999-12-14
- Inventors: Bodo Asmussen; Markus Krumme
- Web page: https://patentgrep.com/patent/US20040024003A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/36: Opioid-abuse
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A flat pharmaceutical preparation which is able to disintegrate in aqueous media and is in the form of a sheet, film, paper or wafer for transmucosal administration of active ingredients in the oral cavity, is characterized by a content of oxycodone, or an active ingredient comparable to oxycodone, or a therapeutically suitable salt of oxycodone or of the pharmacologically comparable active ingredient.

## Claims

### Claim 1

Flat pharmaceutical preparation which is able to disintegrate in aqueous media and is in the form of a sheet, film, paper or wafer for transmucosal administration of oxycodone or of a therapeutically suitable salt of oxycodone in the oral cavity, characterized in that it has a bilayer or multilayer structure, with one of the layers being given bioadhesive or mucoadhesive properties by addition of an adhesion-promoting excipient or excipient mixture, and with the non-bioadhesive or -mucoadhesive layer(s) having a permeability for the active ingredient which is lower than that of the bioadhesive or mucoadhesive layer.

### Claim 2 (depends on 1)

Pharmaceutical preparation according to claim 1, characterized in that it contains at least one other active ingredient for transmucosal administration.

### Claim 3 (depends on 2)

Pharmaceutical preparation according to claim 2, characterized in that the said other active ingredient is suitable for preventing, moderating or delaying a dependence on opiates.

### Claim 4 (depends on 3)

Pharmaceutical preparation according to claim 3, characterized in that the said other active ingredient is able at least partly to act as opiate antagonist.

### Claim 5 (depends on 4)

Pharmaceutical preparation according to claim 4, characterized in that the said other active ingredient is selected from the group comprising nalbuphine, naloxone, naltrexone and levallorphan.

### Claim 6

Pharmaceutical preparation according to one or more of the preceding claims, characterized in that it is in the form of an undivided material in the form of a sheet or ribbon, from which dose units can be separated for the purpose of administration.

### Claim 7

Pharmaceutical preparation according to one or more of the preceding claims, characterized in that it is in a form previously divided dose-wise.

### Claim 8 (depends on 6, 7)

Pharmaceutical preparation according to claim 6 or 7, characterized in that it has an active ingredient content per dose unit which is suitable for analgesia, preferably an active ingredient content of 5-20 mg per dose unit.

### Claim 9 (depends on 6, 7)

Pharmaceutical preparation according to claim 6 or 7, characterized in that it has an active ingredient content per dose unit which is suitable for opiate or cocaine replacement therapy.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

Use of a pharmaceutical preparation according to one or more of claims 1 to 12 for the production of a medicinal product which can be administered orally for pain treatment.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

Use of a pharmaceutical preparation according to one or more of claims 1 to 12 for the production of a medicinal product which can be administered orally for opiate or cocaine replacement therapy or abstinence-achieving therapy.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

Method for the treatment of states of pain by administration of a pharmaceutical preparation according to one or more of claims 1 to 8 onto the oral mucosa.

### Claim 13

Method for the treatment of opiate or cocaine dependence within the framework of an abstinence-achieving or replacement therapy by administration of a mucoadhesive pharmaceutical preparation onto the oral mucosa, with the pharmaceutical preparation containing oxycodone or one of its therapeutically suitable salts as active ingredient, and with said active ingredient being administered in a transmucosal manner.

### Claim 14 (depends on 13)

M thod according to claim 13, characteriz d in that the pharmaceutical preparation used has a bilayer or multilayer structure, with one of the layers being given bioadhesive or mucoadhesive properties by addition of an adhesion-promoting excipient or excipient mixture, and with the non-bioadhesive or -mucoadhesive layer(s) having a permeability for the active ingredient which is lower than that of the bioadhesive or mucoadhesive layer.

### Claim 15 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 14)

Method according to claim 14, characterized in that the pharmaceutical preparation used is a preparation according to claims 2 to 9.
